The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ONVO | -57.75% | -98.08% | -54.59% | -99% |
| S&P | +12.65% | +91.73% | +13.89% | +398% |
Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.
The company's licensing agreement with a Swedish company means an infusion of some much-needed cash for Organovo.
The tissue engineering company reported fiscal fourth-quarter and full-year 2018 results.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.04M | -5.1% |
| Gross Profit | -$0.02M | 27.3% |
| Gross Margin | -64.86% | 19.8% |
| Market Cap | $3.82M | -50.2% |
| Market Cap / Employee | $0.29M | 0.0% |
| Employees | 13 | -35.0% |
| Net Income | -$2.84M | 15.0% |
| EBITDA | -$2.85M | 13.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $9.06M | 46.4% |
| Accounts Receivable | $0.03M | -33.3% |
| Inventory | 0 | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.30M | -61.5% |
| Short Term Debt | $0.52M | 2.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -18.53% | 96.9% |
| Return On Invested Capital | -106.43% | 9.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.94M | -32.1% |
| Operating Free Cash Flow | -$3.94M | -32.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.13 | 21.65 | 8.79 | 0.27 | -87.53% |
| Price to Sales | 88.92 | 68.07 | 29.53 | 25.92 | -83.07% |
| Price to Tangible Book Value | 25.50 | 23.04 | 8.79 | 0.27 | -98.96% |
| Enterprise Value to EBITDA | -2.97 | -2.49 | 1.94 | 1.60 | -184.32% |
| Return on Equity | -206.7% | -378.4% | -35.3% | -24.5% | -83.83% |
| Total Debt | $1.56M | $1.32M | $1.07M | $0.82M | -36.03% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
